The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease
Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, Zhang J, Sun C, Zhang Y, Ju X
European neurology · 48 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2015-01-01 · Eur Neurol · vol. 73 · número 3-4 · págs. 205–211
- Editorial
- Karger Publishers
- Citado
- 76 citas · más que el 90% de estudios similares · 2.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 31 trabajos
- Acceso
- De pago
- Áreas de investigación
- Coenzyme Q10 studies and effects · Parkinson's Disease Mechanisms and Treatments · Biochemical effects in animals
- Palabras clave
- Coenzyme Q10, Montreal Cognitive Assessment, Internal medicine, Medicine, Creatine, Parkinson's disease, Combination therapy, Placebo, Gastroenterology, Physical therapy, Disease, Cognitive impairment, Pathology
- MeSH
- humans, parkinson disease, creatine, ubiquinone, drug therapy, combination, cognition, aged, middle aged, female, male, cognitive dysfunction
10 autores
- Zhenguang Li🇨🇳Binzhou Medical University; Weihai Municipal Hospital
- Pengfei Wang🇨🇳Binzhou Medical University; Weihai Municipal Hospital
- Zhancai Yu🇨🇳Binzhou Medical University; Weihai Municipal Hospital
- Yannan Cong🇨🇳Binzhou Medical University; Weihai Municipal Hospital
- Hairong Sun🇨🇳Binzhou Medical University; Weihai Municipal Hospital
- Jiangshan Zhang🇨🇳Binzhou Medical University; Weihai Municipal Hospital
- Jinbiao Zhang🇨🇳Binzhou Medical University; Weihai Municipal Hospital
- Chao Sun🇨🇳Binzhou Medical University; Weihai Municipal Hospital
- Yong Zhang🇨🇳Binzhou Medical University; Weihai Municipal Hospital
- Xiaohua Ju
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
To investigate the effect of creatine and coenzyme Q10 (CoQ10) combination therapy on mild cognitive impairment (MCI) in Parkinson's disease (PD; PD-MCI) and its influences on plasma phospholipid (PL) levels in PD-MCI.
Methods
The demographic data of 75 PD-MCI patients who enrolled in this collaborative PD study were collected. These patients were evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS) III and the Montreal Cognitive Assessment (MoCA). These 75 PD-MCI patients were randomly treated with creatine monohydrate 5 g b.i.d. and CoQ10 100 mg t.i.d. orally or placebo. MoCA evaluation and PL level measurements were performed after 12 and 18 months of treatment.
Results
After 12 and 18 months of treatment, the differences in the MoCA scores of the combination therapy and control groups were statistically significant (p < 0.05 at 12 months and p < 0.01 at 18 months), and the plasma PL levels of the combination therapy group were significantly lower than those of the control group (p < 0.01 at 12 months and p < 0.001 at 18 months).
Conclusions
Combination therapy with creatine and CoQ10 could delay the decline of cognitive function in PD-MCI patients and could lower their plasma PL levels; therefore, this combination therapy may have a neuroprotective function.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.